Organon & Co | OGN - Net Income


Organon & Co reported $108M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Celltrion KRW 8.82B 64.74M Mar/2026
Cspc Pharmaceutical CNY 370.72M 592.81M Dec/2025
Deva Holding AS TRY 583.98M 319.1M Sep/2023
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Divis Laboratories Ltd INR 9.02B 1.51B Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Kangmei Pharma CNY -16.56M 12.74M Mar/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Laboratorios Farma EUR 103.69M 37.04M Dec/2023
Malin Corporation EUR -1.1M 2.2M Dec/2023
Medical Developments International AUD -226K 121K Dec/2025
Merck USD -1.34B 2.9B Jun/2026
Neuren Pharmaceuticals AUD 15.4M 7.88M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Organigram Holdings CAD -921K 20.89M Mar/2026
Organon & Co USD 108M 38M Jun/2026
Ovoca Bio EUR 4.42M 5.19M Dec/2025
Pharma Mar EUR -972K 2.5M Jun/2026
Qiagen NV USD 103.4M 35.36M Jun/2026
Sartorius EUR 65.9M 9.7M Jun/2026
Sino Biopharmaceutical CNY 3.39B 2.91B Jun/2025
Tilray USD -44.93M 44.61M Sep/2025
Zealand Pharma A/S -394M 14.88M Mar/2026